Track: Networking Session
Track: Hybrid Session
Maria Carlo, MD
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Disclosure(s): No financial relationships to disclose
Tian Zhang, MD, MHS
University of Texas Southwestern Medical Center
Dallas, Texas, United States
Disclosure(s): Contract Research: Astellas/Medivation (Terminated, August 31, 2021); Bristol Meyers Squibb (Terminated, August 31, 2021); Eli Lilly (Terminated, August 31, 2021); Exelixis (Terminated, August 31, 2021); Janssen (Terminated, August 31, 2021); Merck (Terminated, August 31, 2021); Merrimack (Terminated, August 31, 2021); Mirati Therapeutics (Terminated, August 31, 2021); Novartis (Terminated, August 31, 2021); Omniseq (Terminated, August 31, 2021); Pfizer (Terminated, August 31, 2021); Regeneron (Terminated, August 31, 2021)
Non-CE Consulting: Aravive (Ongoing); Aveo (Ongoing); Bayer (Ongoing); Bristol Meyers Squibb (Ongoing); Calithera Biosciences (Ongoing); Dendreon (Ongoing); Eisai (Ongoing); Eli Lilly (Ongoing); Exelixis (Ongoing); Janssen (Ongoing); Merck (Ongoing); Pfizer (Ongoing); QED Therapeutics (Ongoing); Sanofi (Ongoing); SeaGen (Ongoing)
Non-CE Speakers Bureau: Genomic Health (Terminated, December 31, 2020); Sanofi (Terminated, December 31, 2020)
Ownership Interest: I own stocks of the Commercial entity: Nanorobotics (Ongoing)
Salary or Employment Relationship (does not included small non-employed consulting arrangements): Archimmune Therapeutics (Ongoing); Capio Biosciences (Ongoing)
spouse: Archimmune Therapeutics (Ongoing); Capio Biosciences (Ongoing)
Elaine Chang, MD
United States Food and Drug Administration
Disclosure(s): No financial relationships to disclose
Vicki Goodman, MD (she/her/hers)
Exelixis
King of Prussia, Pennsylvania, United States
Disclosure(s): Ownership Interest: I own stocks of the Commercial entity: Bristol Meyers Squibb (Ongoing); Exelixis (Ongoing); GlaxoSmithKline (Ongoing); Merck Sharp & Dohme (Ongoing)
Salary or Employment Relationship (does not included small non-employed consulting arrangements): Exelixis (Ongoing)
W. Kimryn Rathmell, MD, PhD
Vanderbilt University Medical Center
Nashville, Tennessee, United States
Disclosure(s): Contract Research: Incyte (Ongoing); Merck (Ongoing)
Ownership Interest: I own stocks of the Commercial entity: Caribou (Ongoing)
Moderator: Maria Carlo, MD – Memorial Sloan Kettering Cancer Center
Speaker: W. Kimryn Rathmell, MD, PhD – Vanderbilt University Medical Center
Speaker: Elaine Chang, MD – United States Food and Drug Administration
Speaker: Vicki Goodman, MD (she/her/hers) – Exelixis
Moderator: Tian Zhang, MD, MHS – University of Texas Southwestern Medical Center